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Abstract: Antibody-drug conjugate (ADC), as a next generation of antibody therapeutics, is a
combination of an antibody and a drug connected via a specialized linker. ADC has four action steps:
systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the
tumor tissue, and action on cells, such as through drug delivery system (DDS) drugs. An antibody
with a size of about 10 nm has the same capacity for passive targeting as some DDS carriers, depending
on the EPR effect. In addition, some antibodies are capable of active targeting. A linker is stable in the
bloodstream but should release drugs efficiently in the tumor cells or their microenvironment. Thus,
the linker technology is actually a typical controlled release technology in DDS. Here, we focused
on molecular imaging. Fluorescent and positron emission tomography (PET) imaging is useful for
the visualization and evaluation of antibody delivery in terms of passive and active targeting in the
systemic circulation and in tumors. To evaluate the controlled release of the ADC in the targeted
area, a mass spectrometry imaging (MSI) with a mass microscope, to visualize the drug released
from ADC, was used. As a result, we succeeded in confirming the significant anti-tumor activity of
anti-fibrin, or anti-tissue factor-ADC, in preclinical settings by using DDS and molecular imaging.
Keywords: ADC (antibody-drug conjugate); DDS (drug delivery system); molecular imaging;
antibody delivery; controlled release; PET (positron emission tomography); MSI (mass spectrometry
imaging)
1. Introduction
Antibody-drug conjugate (ADC) is a next generation therapeutic antibody. Several ADCs
have been used in clinics already [1–4]. Moreover, a large number of biotech and pharmaceutical
companies are dealing with ADC and are competitively exploiting new ones [5,6]. Over 40 ADCs
are under clinical trials worldwide [1,2,7]. However, the effectiveness of ADCs in treating relapsed
or refractory malignant diseases is their most important aspect. SGN-35 is effective for patients
with CD30-positive relapsed or refractory malignant lymphoma [8–10]. T-DM1 is also effective for
patients with HER2-positive advanced or remnant breast cancer previously treated with standard dugs,
including the naked anti-HER2 antibody [10,11]. Hence, ADC has been expected to be a breakthrough
drug following the immune checkpoint blockades.
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ADC has three parts: antibody, linker, and drug. An antibody is a large molecular-sized carrier,
which has the ability for passive targeting depending on the enhanced permeability and retention
(EPR) effect [12,13]. It is also capable of active targeting depending on the specific recognition and
binding to the target antigen [5,14]. A linker is stable in the bloodstream but should efficiently release
the drug in the tumor cells or within their microenvironment [2,6,15]. The total number of drugs
conjugated with a single antibody molecule is about four, but can be up to eight. Therefore, highly
toxic agents are strongly required [1,2,6,15]. Pharmacologically, ADC has four action steps: systemic
circulation, the EPR effect including passive targeting, penetration within the tumor tissue, and action
on cells, which includes active targeting and controlled release. This mechanism is similar to drug
delivery system (DDS) drugs, such as liposome or micelle (Figure 1). The linker technology is a typical
controlled release technology in DDS. It is clear that ADC should belong to the DDS drug category.
Here, we focused on molecular imaging which helps visualize the antibody delivery throughout the
four steps, including the controlled release in the final step. Here, we review the development of ADC
and our recent research works using DDS and molecular imaging.
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Figure 1. Structure and drug delivery of antibody-drug conjugate (ADC). ADC has three parts: 
antibody, linker, and drug. ADC has four action steps: systemic circulation, enhanced permeability 
and retention (EPR) effect, penetration, and action on cells, like drug delivery system (DDS) drugs. 
2. Antibody–Drug Conjugate 
ADC technologies have been developed for the targeted delivery of agents while minimizing 
their adverse effects. First-generation ADCs were produced with murine-derived antibody 
backbones. Therefore, an anti-mouse antibody generated in the human body (HAMA, human anti-
mouse antibody) accelerated the clearance of ADCs by host immune reaction. The linkers were not 
stable enough in the bloodstream. Collectively, ADCs themselves showed a short half-life in the 
human body. Moreover, the drugs used as a payload (IC50, half maximal (50%) inhibitory 
concentration; μM level) were not toxic enough to be significantly effective in human subjects. 
Figure 1. Structure and drug delivery of antibody-drug conjugate (ADC). ADC has thr e parts:
antibody, li ker, . s f r ti t : s ste ic circ lation, e anced er eability
and retention (EP ) effect, e etrati , cti ll , li li .
2. Antibody–Drug Conjugate
ADC technologies have been developed for the targeted delivery of agents hile ini izing
their adverse effects. First-generation ADCs were produced with murine-derived antibody backbones.
Therefore, an anti-mouse antibody generated in the human body (HAMA, human anti-mouse antibody)
accelerated the clearance of ADCs by host immune reaction. The linkers were not stable enough in the
bloodstream. Collectively, ADCs themselves showed a short half-life in the human body. Moreover,
the drugs used as a payload (IC50, half maximal (50%) inhibitory concentration; µM level) were
not toxic enough to be significantly effective in human subjects. Consequently, ADCs dropped out
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of clinical trials. In addition, the FDA-approved Gemtuzumab ozogamicin was also withdrawn
from the market because of serious toxicities. However, recent advances in bioengineering have
improved these drawbacks, resulting in the emergence of second generation ADCs. Since then,
many methods have been used to improve both the stability in the bloodstream and the controlled
drug release in the targets, which has led to demonstrating clinical effectiveness, including SGN-35,
anti-CD30 chimeric antibody (human constant regions with down-sized mouse variable regions) with
monomethyl auristatin E (MMAE, IC50; nM level) via valine-citrulline (cathepsin cleavable) linker
and T-DM1, anti-HER2 humanized antibody (largely human component with minimized mouse CDR
segment) with Maytansine (IC50; nM level) via a thioester (noncleavable) linker, which have lower
immunogenicity [1,2,5,10].
The heterogeneity of the drug-antibody ratio (DAR), which is the number of drug molecules
loaded onto single antibody, is an important issue in the development of the third generation ADCs.
DAR can accelerate the clearance and weaken the efficacy of ADCs. To produce homogeneous
ADCs, site-specific drug conjugation methods have been developed, including THIOMAB as a
cysteine replacement strategy, or SMARTagTM, SMAC-TAGTM, and TG-ADCTM as chemo-enzymatic
strategies [10]. In addition, novel technologies, such as bispecific antibodies or bispecific T-cell engager
(BiTE), have been applied for increasing efficacy. Furthermore, a novel combination approach with
immune checkpoint blockades, or an application of immune-oncology agents as a payload, would be
promising for achieving a durable response in clinics [10,16,17].
Thus, an evaluation and modification of antibody delivery and controlled drug release is
important for ADC development.
3. Antibody Delivery and the EPR Effect
High molecular weight (HMW) agents, in the range of about 10–200 nm can extravasate easily
from leaky tumor vessels due to the immature structure with intercellular openings and the increased
vascular permeability factor, such as VEGF or Kallikrein-Kinin [12,13,18]. In addition, because of the
lack of lymphatic vessels acting as a drainage system for HMW agents, they can stay in the tumor for a
long time. This mechanism is specific for cancer and is called the EPR effect [12,13,19]. An antibody,
typically IgG with a size of about 10 nm acting as a HMW agent, can selectively accumulate in the
tumor even if it is a non-specific antibody. This is the passive targeting of an antibody, and the
mechanism depends on the EPR effect [13,19,20]. Moreover, a specific antibody can accumulate more
and stay longer in the tumor than a non-specific antibody, which is called active targeting [13,19,20].
Interestingly, small-sized IgG fragments, such as Fab, accumulate in the tumor but stay less time
than the specific antibody IgG, because the passive targeting ability has been lost, as seen in small
compounds such as a low molecular weight (LMW) agent. Small-sized IgG fragments are also
eliminated from the kidney. The absence of passive targeting and rapid renal clearance lead a loss of
the long-term accumulation seen in its IgG counterpart. Finally, by using in vivo imaging, we found
that specific Fab showed the same tumor accumulation as non-specific IgG (Figure 2a). These results
indicated the importance of molecular imaging for observing antibody delivery in vivo.
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panel) in which cancer cells (blue) were surrounded by dense stromal collagen 4 (brown). The middle 
panel shows the in vivo imaging of fluorescent anti-CD 20 and anti-EpCAM antibody that were 
injected into the ML and PC model, respectively. The right panel shows the distribution of anti-CD 
20 and anti-EpCAM antibody (both green) within a ML tumor and PC tumor. The blood vessels, 
yellow in the upper panel and magenta in the lower panel, were also observed. 
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The prognosis for brain tumor glioblastoma (GBM) and pancreatic cancer (PC) remains quite poor 
[21–24]. GBM also involves a blood brain tumor barrier (BBTB) [22,23]. PC involves hypovascularity 
and a low blood supply [21]. These are all disadvantages for drug delivery. In addition, within tumor 
tissues, dense tumor stroma can block the penetration of the drugs [19,25–28], so most drugs cannot 
reach the cancer cells. This is called the stromal barrier [25–28]. In order to visualize the stromal 
barrier, we conducted in vivo imaging using fluorescent antibodies. Two types of models including 
malignant lymphoma (ML) that has less stroma and PC with dense stroma, were prepared and 
treated with cancer-specific anti-CD20 or the anti-EpCAM antibody, respectively [27]. Large amounts 
of accumulation, caused by both passive targeting and active targeting, were observed in both tumor 
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4. Antibody Delivery and Tissue Penetration
The prognosis for brain tumor glioblastoma (GBM) and pancreatic cancer (PC) remains quite
poor [21–24]. GBM also involves a blood brain tumor barrier (BBTB) [22,23]. PC involves
hypovascularity and a low blood supply [21]. These are all disadvantages for drug delivery. In addition,
within tumor tissues, dense tumor stroma can block the penetration of the drugs [19,25–28], so most
drugs cannot reach the cancer cells. This is called the stromal barrier [25–28]. In order to visualize
the stromal barrier, we conducted in vivo imaging using fluorescent antibodies. Two types of models
including malignant lymphoma (ML) that has less stroma and PC with dense stroma, were prepared
and treated with cancer-specific anti-CD20 or the anti-EpCAM antibody, respectively [27]. Large
amounts of accumulation, caused by both passive targeting and active targeting, were observed in both
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tumor models at seven days after the administration. Macroscopically, antibody delivery appeared
successful in both tumor models. Microscopically, in the ML tumor, anti-CD20 antibody penetrated
deeply into the whole tumor area, showing good distribution. On the other hand, distribution of the
anti-EpCAM antibody was restricted to the peripheral area neighboring the tumor vessels. There was
no clear signal in the central area. The penetration of the antibody was clearly inhibited by the tumor
stroma (Figure 2b).
To overcome this drawback, we developed anti-fibrin ADC [29] and anti-tissue factor (TF)
ADC [30]. The former was named by cancer stromal targeting (CAST) therapy [13,31]. In conventional
ADC, the target is the cell-surface protein of cancer cells and an intracellular drug-release type linker is
used. After the internalization, the drug can be released. On the other hand, in CAST-ADC, the target
is the tumor stroma and not the cell, and an extracellular drug-release type linker is used. The drug
can be released outside of the cells, just on the stroma without internalization [26,27,29,31]. For the
anti-TF-ADC, an anti-TF antibody binds strongly to both the tumor and stromal cells expressing TF, and
can be used for simultaneous targeting of tumor and stromal cells compared to a typical CAST-ADC.
5. Immuno-PET Imaging
We used a positron emission tomography (PET) system to evaluate the antibody delivery [32].
The antibody was labeled with a positron-emitting radionuclide as a tracer. The PET system can
enable visualization of the antibody delivery from pairs of gamma rays emitted indirectly by the
labeled tracer [33]. This immuno-PET is better than fluorescent imaging for deep tissue imaging
because of its high sensitivity and accurate quantification. 64Cu with a half-life of 13 hours, 76Br
with a half-life of 16 hours, or 89Zr with a half-life of 72 hours, all having a relatively long physical
half-life, are usually used for immuno-PET imaging [33–35]. Among them, 89Zr, which has a half-life
of about three days, is the most commonly used for labeling antibodies worldwide, because the
antibody also has long half-life of about three to seven days, and three days are required to acquire
good contrast imaging after administration [34,36,37]. We conducted immuno-PET imaging of the
89Zr-labeled anti-fibrin antibody in a chemically-induced mouse skin cancer model similar to human
skin cancer [32]. The anti-fibrin antibody selectively accumulated in the tumor. Serial PET imaging
clearly showed skin cancers with 89Zr-labeled anti-fibrin antibody (Figure 3a). Quantification of the
PET images indicated that the accumulation of the 89Zr-labeled anti-fibrin antibody in the tumor
increased with time and peaked on day five after administration, while the control antibody did not
show a time-dependent increase in tumor uptake (Figure 3b). Comparison of fibrin immunostaining
and autoradiography confirmed the selective localization of the 89Zr-labeled anti-fibrin antibody in
the fibrin-positive tumor stroma (Figure 3c). Furthermore, we used PET/CT imaging which clearly
indicated that the area showing high uptake of anti-fibrin antibody coincided with the tumor area,
detected by CT scan (Figure 3d). We were able to confirm the effective delivery and tumor specificity
of the anti-fibrin antibody. Lastly, we succeeded in confirming the significant anti-tumor activity of
anti-fibrin CAST-ADC in a preclinical setting.
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diagnostic ability and contribute to the better management of cancer patients. Although 18F-FDG and 
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clinics, the use of a radionuclide-labeled antibody as a targeting PET probe has been progressively 
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increasingly used around the world. Using a companion diagnostic for the determination of the 
indicated treatment (e.g., the patient with HER2 positive breast cancer for T-DM1 treatment) is 
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(a)–(b) PET imaging analysis was conducted using an 89Zr-labeled anti-fibrin antibody on day zero,
one, two, three, five, and seven after the administration and %ID/g showed the relative value of Day 0
(100%). (c) With autoradiogram examination, the 89Zr-labeled anti-fibrin antibody was accumulated
within the fibrin-positive tumor stroma, as represented by the dashed black line. (d) In PET/CT, the
89Zr-labeled anti-fibrin antibody showed clear and specific accumulation in the tumor. Adapted from
Hisada et al. [32].
More recently, PET/MRI has been used for molecular imaging [38]. Hybrid imaging, combining
functional information from PET with morphological information by CT/MRI, is expected to improve
diagnostic ability and contribute to the better management of cancer patients. Although 18F-FDG and
11C-methionine, as part of a PET probe for targeting cellular metabolism, have been widely used in
clinics, the use of a radionuclide-labeled antibody as a targeting PET probe has been progressively
increasing in clinics [33,36,39,40]. In addition, many therapeutic antibodies, including ADC, will
be increasingly used around the world. Using a co panion diagnostic for the determination of
the indicated tre tment (e.g., the patie t with HER2 positive breast cancer f r T-DM1 reatment)
is important [36,39,41,42]. In general, although an immunohistochemistry assay is use for the
companion diagnosis, a biopsy specimen is needed. However, obtaining a biopsy from a patient
with metastasis in deep organs, such as the brain or bone, is difficult [36,43]. Therefore, immuno-PET
could be applied in those cases. Moreover, it can provide a non-invasive test instead of an invasive
surgical biopsy. Therefore, immuno-PET would be useful for precision medicine as well as ADC
development [33,36].
6. Mass Spectrometry Imaging
Mass spectro etry imaging (MSI) is a method to vie a biomolecule or metabolite i a tissue
sample by usi g mass spectrometry [44–49]. Ionization of the argeted m lecules is important
for the mass analysis. For the ionization, several methods exist, such as Matrix-Associated Laser
Desorption/Ionization (MALDI) or Electrospray Ionization (ESI) [44–46]. ESI is capable of ionizing
a wide range of molecules, including chemical compounds without the addition of a matrix under
ambient conditions. The analysis can be performed in conjunction with liquid chromatography with
mass spectrometry (LC-MS).
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For MALDI, the matrix should be sprayed on the tissue sample. After the laser irradiates the
treated sample, ion exchange occurs between the ionized matrixes transfer protons and the analyte
molecules (biomolecules and metabolites). Finally, the molecules become ionized. Mass analysis
of the ionized molecules can be conducted by using Time-Of-Flight MS (TOF-MS) [44,45]. TOF-MS
uses a simple principle to calculate the molecule size according to the difference in the flight time.
Lighter ions of the same charge reach higher speeds, whereas heavier ones are slower. Therefore, the
mass-to-charge ratio (m/z) of each ion can be determined by measuring the velocity. If we selected
the molecule with specialized m/z, we can identify the molecule itself and semi-quantify it in the
examination area.
Briefly, MALDI imaging provides an enormous amount of information on the abundance and
distribution of the targeted molecules within tissue samples with high sensitivity and high spatial
resolution [44,45]. A suitable matrix should be selected for an efficient ionization, although it is
difficult for some molecules to achieve it. On the other hand, ESI-MSI allows direct tissue analysis
without matrix-preparation [46,48,49]. As a drawback, the spatial resolution is poor when compared
with MALDI-MSI.
The new MSI analyzer, namely the mass microscope, is a microscope coupled with a
high-resolution atmospheric pressure-laser desorption/ionization and quadruple ion trap TOF
analyzer, has improved the tissue resolution of MALDI-MSI [50–54]. It has a resolution of 10 µm or
less, which is advantageous for evaluating the drug distribution in specific cells or areas of interest
within tissues. The mass microscope also allows an image from MSI to be overlaid on an optical image
in the same sample, which is beneficial for understanding and analyzing the tissues of interest. Here,
we hypothesized that MSI using a mass microscope should be able to be applied for the evaluation of
the controlled release of ADC in the targeted area (Figure 4a,b) [50].
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of the limitation on the sensitivity. A single ADC only has about four drug molecules, or eight at most. 
Our concern was that the concentration of the released drug might be below the detection limit. We 
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7. Visualization of the Controlled Release
Before the MSI examination, we thought it might be difficult to detect the drug signal because
of the limitatio on the sensitivity. A single ADC only has about four drug molecules, or eight at
most. Our concern was that the concentration of the released drug might be below the detection limit.
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We decided to evaluate the paclitaxel (PTX)-incorporated micelle [13,55] as a DDS drug, which initially
contained about 200 PTX molecules. Free PTX (fPTX), as a conventional control and released PTX
(rPTX) from micelles, were detected in the tumor. A fPTX signal was detected at 15 min and one hour
after the administration, but decreased at six hours and disappeared by 24 hours. In contrast to fPTX,
a rPTX signal was detected from 15 min to 72 hours after administration. The signal intensity was
greatest at 24 hours (Figure 5a). Next, we conducted drug imaging in normal neuronal tissue. A strong
fPTX signal was detected in the perineuronal lesion at 30 min and one hour after the administration.
By contrast, the rPTX signal from PTX-micelle was extremely weak around the neuron (Figure 5b). This
is a significant difference and the reason why PTX-micelle does not cause neurotoxicity [13]. We thus
succeeded in visualizing the EPR effect for the first time [50].
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Subsequently, we wanted to visualize the anti-tissue factor antibody-drug conjugate  
(anti-TF-ADC) (Figure 6a) [51]. Monomethyl auristatin E (MMAE) was used as a payload [1–3,8,9]. 
The molecular weight (MW) of MMAE is 717.5. The three positive-ion peaks are derived from 
MMAE: 718.4, 740.4, and 756.4 m/z as a single-charge hydrogen [M + H]+, sodium [M + Na]+, and 
potassium [M + K]+, respectively, were observed by MS analysis. We then examined the MS/MS 
fragments of MMAE from each of the three positive-ion peaks. Among them, we selected the prominent 
fragment 496.3 m/z detected when 740.4 m/z was used as a precursor ion. In the validation tests, the 
specificity of 496.3 m/z, as a MMAE-specific fragment peak, was confirmed. We thus succeeded in 
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Figure 5. Visualization of the controlled release of PTX-incorporated micelle. (a) In tumor tissue, the
bright field (upper), reference substance (mid le, a arbitrary signal of 824.6 m/z), and PTX (lower,
specific s gnal of 892.3 m/z). (b) In normal tis right field (u per), neuronal marker (middle,
sphingomyelin-specific signal of 851.6 m/z), and P er, specific signal of 892.3 m/z). The neuronal
area is delineated by a white line. Adapted from as a a et al. [50].
Subsequently, we wanted to visualize the anti-tissue factor antibody-drug conjugate
(anti-TF-ADC) (Figure 6a) [51]. Monomethyl auristatin E (MMAE) was used as a payload [1–3,8,9].
The molecular weight (MW) of MMAE is 717.5. The three positive-ion peak are derived from MMAE:
718.4, 740.4, and 756.4 m/z as a single-charge hydrogen [M + H]+, sodium [M + Na]+, and potassium
[M + K]+, respectively, were observed by MS analysis. We then examined the MS/MS fragments of
MMAE from each of the three positive-ion peaks. Among them, we selected the prominent fragment
496.3 m/z detected when 740.4 m/z was used as a precursor ion. In the validation tests, the specificity
of 496.3 m/z, as a MMAE-specific fragment peak, was confirmed. We thus succeeded in visualizing
and quantifying MMAE separately from other biomolecules (Figure 6b) [51]. In an in vitro study, the
intensities of the mAbs, ADCs, and each MMAE sample were measured. The signal intensity of free
MMAE increased in a concentration-dependent manner. Moreover, the signal intensities obtained from
1.0 µL of 1.0-µM human TF DC and the con rol ADC were far weaker tha those from 1.0 µL of 1.0-µM
MMAE alone. Therefore, the MMAE signal in tumor ti sues, after the ADC trea ment, was largely
released MMAE. These observations were a le to be performed i a stable and reproducible manner,
with a high-resolution atmospheric pressure mass microscope (Figure 6c). We then concluded that
the controlled release of ADC can be visualized and quantified by MSI. Control ADC or anti-TF-ADC
was administered into a mouse bearing a human pancreatic cancer tumor. In the examination of
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the tumor samples by MSI, a strong released MMAE signal from anti-TF-ADC was detected when
compared to that of the control-ADC. The signal was strongest at 24 h after the administration. The
data was validated by LC-MS analysis [51]. We concluded that ADC distribution and controlled drug
release were successful in the tumor area (Figure 7) [51]. In accordance with these results, a significant
anti-tumor effect of anti-TF ADC has been recognized in the xenograft model of PC [30].
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8. Conclusions
We described our recent work in the development of ADCs as follows. 1) ADC, as a next
generation of antibody therapeutics, has been expected to be a breakthrough drug following the
immune checkpoint blockades. 2) ADC has four action steps: systemic circulation, the EPR effect
which is passive targeting, penetration within the tumor tissue, and action on cells, which involves the
active targeting and controlled release, like DDS drugs. Therefore, the evaluation of both antibody
delivery and controlled release is important. 3) Fluorescent/PET imaging and MSI are useful for the
evaluation of antibody delivery and controlled release, respectively, in ADC research, development,
and medicine. 4) We successfully developed novel ADCs, anti-fibrin-ADC, anti-tissue factor (TF)-ADC,
and others [26,27,29–31,56] by using DDS and molecular imaging.
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